AstraZeneca (LON:AZN) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, Digital Look reports. They currently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price points to a potential upside of 38.69% from the company’s previous close.

Several other research firms also recently issued reports on AZN. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada restated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £117 price objective on shares of AstraZeneca in a research note on Tuesday, September 29th. Finally, Berenberg Bank reiterated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a report on Wednesday, October 7th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Stock Up 1.8%

Shares of LON AZN traded up GBX 218 during midday trading on Tuesday, hitting £126.18. 4,114,209 shares of the stock traded hands, compared to its average volume of 28,242,359. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a one year low of £114.04 and a one year high of £157.32. The business has a 50 day moving average price of £121.01 and a two-hundred day moving average price of £131.12. The company has a market cap of £195.69 billion, a PE ratio of 18.89, a P/E/G ratio of 0.86 and a beta of 0.20.

Insider Activity at AstraZeneca

In related news, insider Michel Demare bought 2,500 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were bought at an average price of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is currently owned by company insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.